secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0000950170-25-000092
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025
--------------------------------------------------------------

- Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.
- Annual base salary of $475,000; target annual bonus of 45% of base salary.
- Inducement equity: option for 650,000 shares and 160,000 RSUs, vesting over 4 and 3 years.
- Kristin Abate, interim principal financial officer, will step down on Jan 3, 2025.
- Severance includes one month base salary per month of service (max 12 months), enhanced upon change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/0000950170-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/kpti-20250102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer